欧洲儿童间质性肺疾病的医疗资源利用与医疗费用
基于欧洲10国Kids Lung Register中445例儿童间质性肺疾病(chILD)患者的纵向医疗资源利用模式,估算每3个月的人均直接医疗、直接非医疗和间接费用。随访至5年期间直接医疗费用下降,而间接和非医疗费用保持稳定。
核心结论
- chILD与高医疗服务利用相关,给医疗系统带来显著经济负担。
研究设计与样本
- 基于Kids Lung Register中10个欧洲国家445例chILD患儿的纵向医疗资源利用模式的前瞻性纵向研究。
- 采用儿童适配的FIMA问卷评估各国利用模式,并以德国单位成本计价。
- 通过伽马分布广义线性回归模型识别费用及其驱动因素。
主要发现
- 基线期(入组前3个月)住院率和住院天数高。
- 随访至5年期间直接医疗费用下降,间接和非医疗费用保持稳定。
临床怎么用
- 临床需关注chILD患儿的高住院率和直接医疗费用负担。
- 费用驱动因素因疾病类别和国家而异,资源规划应考虑这些差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: No data on healthcare utilisation and associated costs for the many rare entities of children's interstitial lung diseases (chILD) exist. This paper portrays healthcare utilisation structures among individuals with chILD, provides a pan-European estimate of a 3-month interval per-capita costs and delineates crucial cost drivers. METHODS: Based on longitudinal healthcare resource utilisation pattern of 445 children included in the Kids Lung Register diagnosed with chILD across 10 European countries, we delineated direct medical and non-medical costs of care per 3-month interval. Country-specific utilisation patterns were assessed with a children-tailored modification of the validated FIMA questionnaire and valued by German unit costs. Costs of care and their drivers were subsequently identified via gamma-distributed generalised linear regression models. RESULTS: During the 3 months prior to inclusion into the registry (baseline), the rate of hospital admissions and inpatient days was high. Unadjusted direct medical per capita costs (€19 818) exceeded indirect (€1 907) and direct non-medical costs (€1 125) by far. Country-specific total costs ranged from €8 713 in Italy to €28 788 in Poland. Highest expenses were caused by the disease categories 'diffuse parenchymal lung disease (DPLD)-diffuse developmental disorders' (€45 536) and 'DPLD-unclear in the non-neonate' (€47 011). During a follow-up time of up to 5 years, direct medical costs dropped, whereas indirect costs and non-medical costs remained stable. CONCLUSIONS: This is the first prospective, longitudinal study analysing healthcare resource utilisation and costs for chILD across different European countries. Our results indicate that chILD is associated with high utilisation of healthcare services, placing a substantial economic burden on health systems.
引用
- Seidl E, Schwerk N, Carlens J, et al. Healthcare resource utilisation and medical costs for children with interstitial lung diseases (chILD) in Europe. Thorax. 2022. PMID: 35149583. doi:10.1136/thoraxjnl-2021-217751
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。